Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.
Alberto Farolfi, MD, PhD
Advertisement
Alberto Farolfi, MD, PhD, is a medical oncologist at Romagnolo Scientific Institute for the Study and Treatment of Tumors
Articles by Alberto Farolfi, MD, PhD
Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5